keyword
MENU ▼
Read by QxMD icon Read
search

Exenatide

keyword
https://www.readbyqxmd.com/read/28098360/morroniside-a-secoiridoid-glycoside-from-cornus-officinalis-attenuates-neuropathic-pain-by-activation-of-spinal-glucagon-like-peptide-1-receptors
#1
Meng Xu, Hai-Yun Wu, Hao Liu, Nian Gong, Yi-Rui Wang, Yong-Xiang Wang
BACKGROUND AND PURPOSE: Iridoid glycosides with intact double bond scaffold of cyclopentapyran were reversible and orthosteric agonists of glucagon-like peptide-1 (GLP-1) receptors and possess antinociception and neuroprotection. Morroniside, derived from the medicinal herb Cornus officinalis, is an atypical secoiridoid replaced by a six-membered cyclic inner ether fragment. This study investigated whether morroniside was an orthosteric GLP-1 receptor agonist and had antihypersensitivity activities in neuropathy...
January 18, 2017: British Journal of Pharmacology
https://www.readbyqxmd.com/read/28097882/antidiabetic-agents-and-cardiovascular-outcomes-in-patients-with-heart-diseases
#2
Judy W M Cheng, Hisham A Badreldin, Dhiren K Patel, Snehal H Bhatt
This article reviews evidence of benefits and risk of antidiabetic agents in cardiovascular (CV) outcomes, with a focus on medications approved by the FDA since 2008. Peer-reviewed articles were identified from MEDLINE and Current Content database (both 1966 to October 1, 2016) using the search terms insulin, metformin, rosiglitazone, pioglitazone, glyburide, glipizide, glimepiride, acarbose, miglitol, albiglutide, exenatide, liraglutide, lixisenatide, dulaglutide, pramlintide, meglitinide, alogliptin, linagliptin, saxagliptin, sitagliptin, canagliflozin, dapagliflozin, empagliflozin, colesevalam, bromocriptine, mortality, myocardial infarction (MI), heart failure, (HF) and stroke...
January 18, 2017: Current Medical Research and Opinion
https://www.readbyqxmd.com/read/28096223/combination-therapy-with-exenatide-plus-pioglitazone-versus-basal-bolus-insulin-in-poorly-controlled-patients-with-type-2-diabetes-on-sulfonylurea-plus-metformin-the-qatar-study
#3
Muhammad Abdul-Ghani, Osama Migahid, Ayman Megahed, John Adams, Curtis Triplitt, Ralph A DeFronzo, Mahmoud Zirie, Amin Jayyousi
OBJECTIVE: The Qatar Study was designed to examine the efficacy of combination therapy with exenatide plus pioglitazone versus basal-bolus insulin in patients with long-standing poorly controlled type 2 diabetes mellitus (T2DM) on metformin plus a sulfonylurea. RESEARCH DESIGN AND METHODS: The study randomized 231 patients with poorly controlled (HbA1c >7.5%, 58 mmol/mol) T2DM on a sulfonylurea plus metformin to receive 1) pioglitazone plus weekly exenatide (combination therapy), or 2) basal plus prandial insulin (insulin therapy) to maintain HbA1c <7...
January 17, 2017: Diabetes Care
https://www.readbyqxmd.com/read/28093996/challenges-related-to-glycemic-control-in-type-2-diabetes-mellitus-patients
#4
Masoumeh Kheirandish, Hamidreza Mahboobi, Maryam Yazdanparast, Mohammad Amjad Kamal
Diabetes mellitus (DM) is a chronic disease with long-term complications. Glycemic control is an important part in management of DM. The first line in treatment of type 2 DM (T2DM) is diet and life style change. Metformin is the first choice of medication in T2DM patients. Sulfonylureas have high risk of hypoglycemia. Glinides are associated with lower risk of hypoglycemia in comparison to sulfonylureas. Also α-glucosidase inhibitors decrease the polysacarides digestion in small intestine and less effective in comparison to metformin and sulfonylureas in lowering hemoglobin A1c (HbA1c)...
January 15, 2017: Current Drug Metabolism
https://www.readbyqxmd.com/read/28086882/differential-effects-of-glucagon-like-peptide-1-receptor-agonists-on-heart-rate
#5
REVIEW
Martin Lorenz, Francesca Lawson, David Owens, Denis Raccah, Christine Roy-Duval, Anne Lehmann, Riccardo Perfetti, Lawrence Blonde
While glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are known to increase heart rate (HR), it is insufficiently recognized that the extent varies greatly between the various agonists and is affected by the assessment methods employed. Here we review published data from 24-h time-averaged HR monitoring in healthy individuals and subjects with type 2 diabetes mellitus (T2DM) treated with either short-acting GLP-1 RAs, lixisenatide or exenatide, or long-acting GLP-1 RAs, exenatide LAR, liraglutide, albiglutide, or dulaglutide (N = 1112; active-treatment arms)...
January 13, 2017: Cardiovascular Diabetology
https://www.readbyqxmd.com/read/28078541/glucagon-like-peptide-1-receptor-agonist-glp-1ra-therapy-adherence-for-patients-with-type-2-diabetes-in-a-medicare-population
#6
Hiep Nguyen, Robert Dufour, Amanda Caldwell-Tarr
INTRODUCTION: Anti-diabetes medication regimen adherence is a clinical challenge in elderly patients with type 2 diabetes (T2D) and other comorbidities associated with aging. Glucagon-like peptide-1 receptor agonists (GLP-1RA) therapies such as exenatide once weekly (QW), exenatide twice daily (BID), and liraglutide once daily (QD) are an increasingly used class of drugs with proven efficacy and tolerability. Real-world evidence on adherence to GLP-1RAs in elderly or disabled patients is limited...
January 11, 2017: Advances in Therapy
https://www.readbyqxmd.com/read/28070733/glp-1-ra-treatment-patterns-among-type-2-diabetes-patients-in-five-european-countries
#7
Victoria Divino, Mitch DeKoven, Farhad Ali Khan, Kristina S Boye, Hélène Sapin, Kirsi Norrbacka
INTRODUCTION: Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are a relatively new class of injectable drugs used in the treatment of type 2 diabetes (T2D). This retrospective database study evaluated real-world treatment patterns of T2D patients initiating GLP-1 RAs in Belgium (BE), France (FR), Germany (DE), The Netherlands (NL) and Sweden (SE). METHODS: Adult T2D patients initiating exenatide twice daily (exBID), exenatide once weekly (exQW), liraglutide (LIRA) or lixisenatide (LIXI) during 2013 were identified using the QuintilesIMS (QuintilesIMS, Durham, NC, and Danbury, CT, USA) longitudinal retail pharmacy databases (LRx; BE/FR/DE/NL) and national health register data (SE)...
January 9, 2017: Diabetes Therapy: Research, Treatment and Education of Diabetes and related Disorders
https://www.readbyqxmd.com/read/28058769/upper-and-or-lower-gastrointestinal-adverse-events-with-glp-1-receptor-agonists-incidences-and-consequences
#8
Michael Horowitz, Vanita R Aroda, Jenny Han, Elise Hardy, Chris K Rayner
AIMS: Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are associated with gastrointestinal adverse events (AEs), although type and frequency may differ across the class. We characterized gastrointestinal AEs with different GLP-1RAs. METHODS: Two retrospective intent-to-treat analyses of 6-month patient-level data were conducted. Data from three studies comparing exenatide once weekly (QW; n = 617) with exenatide twice daily (BID; n = 606) were pooled, and one (DURATION-6) comparing exenatide QW (n = 461) with liraglutide (n = 450) was analyzed separately...
January 6, 2017: Diabetes, Obesity & Metabolism
https://www.readbyqxmd.com/read/28058656/evaluating-the-long-term-cost-effectiveness-of-daily-administered-glp-1-receptor-agonists-for-the-treatment-of-type-2-diabetes-in-the-united-kingdom
#9
Barnaby Hunt, Qing Ye, William J Valentine, Donna Ashley
INTRODUCTION: The glucagon-like peptide-1 (GLP-1) receptor agonist class has grown in the last decade, with several agents available in the UK. However there is currently a paucity of evidence regarding the relative cost-effectiveness of liraglutide 1.2 mg versus other daily administered GLP-1 receptor agonists, due to a lack of head-to-head trial data. Therefore the present analysis was performed, using results from a network meta-analysis (NMA), to compare the cost-effectiveness of three currently available daily administered GLP-1 receptor agonists for treatment of diabetes in the UK setting...
January 5, 2017: Diabetes Therapy: Research, Treatment and Education of Diabetes and related Disorders
https://www.readbyqxmd.com/read/28029018/exenatide-versus-insulin-lispro-added-to-basal-insulin-in-a-subgroup-of-korean-patients-with-type-2-diabetes-mellitus
#10
Kun Ho Yoon, Elise Hardy, Jenny Han
BACKGROUND: The prevalence of type 2 diabetes mellitus (T2DM) and obesity is increasing in Korea. Clinical studies in patients with T2DM have shown that combining the glucagon-like peptide-1 receptor agonist exenatide twice daily with basal insulin is an effective glucose-lowering strategy. However, these studies were predominantly conducted in non-Asian populations. METHODS: We conducted a subgroup analysis of data from a multinational, 30-week, randomized, open-label trial to compare the effects of exenatide twice daily (n=10) or three times daily mealtime insulin lispro (n=13) among Korean patients with T2DM inadequately controlled (glycosylated hemoglobin [HbA1c] >7...
December 26, 2016: Diabetes & Metabolism Journal
https://www.readbyqxmd.com/read/28008585/glucagon-like-peptide-1-analogues-inhibit-proliferation-and-increase-apoptosis-of-human-prostate-cancer-cells-in-vitro
#11
X-N Li, H-M Bu, X-H Ma, Sh Lu, Sh Zhao, Y-L Cui, J Sun
Background: Research has shown that the incidence of prostate cancer is increased in patients with type 2 diabetes mellitus (T2DM) 1. Glucagon-like peptide-1 (GLP-1) is a gastrointestinal hormone that enhances glucose-dependent insulin secretion and suppresses glucagon release. Method: Here, we examined the effect of exenatide and liraglutide, 2 types of GLP-1 analogues, on prostate cancer cells growth by CCK-8 assay, Hoechst33258 staining assay, and western blot analysis of apoptosis-related proteins Bax and Bcl-2...
December 22, 2016: Experimental and Clinical Endocrinology & Diabetes
https://www.readbyqxmd.com/read/27995593/exenatide-add-on-to-continuous-subcutaneous-insulin-infusion-therapy-reduces-bolus-insulin-doses-in-patients-with-type-2-diabetes-a-randomized-controlled-open-label-trial
#12
Feng-Fei Li, Lanlan Jiang, Liyuan Fu, Hong-Hong Zhu, Peihua Zhou, Danfeng Zhang, Xiao-Fei Su, Jin-Dan Wu, Lei Ye, Jian-Hua Ma
INTRODUCTION: The objective of this study was to investigate the effect of adding exenatide to continuous subcutaneous insulin infusion (CSII) therapy on the precise insulin doses required by type 2 diabetic patients to maintain glycemic control. METHODS: This was a single-center, randomized, controlled, open-label trial. Uncontrolled T2D patients were recruited between March 2010 and November 2011 at Nanjing First Hospital, China. Subjects were randomly assigned (1:1) to either an exenatide add-on to CSII group or a CSII therapy only (i...
December 19, 2016: Diabetes Therapy: Research, Treatment and Education of Diabetes and related Disorders
https://www.readbyqxmd.com/read/27981757/efficacy-and-safety-of-glucagon-like-peptide-1-receptor-agonists-in-type-2-diabetes-systematic-review-and-mixed-treatment-comparison-analysis
#13
Zin Z Htike, Francesco Zaccardi, Dimitris Papamargaritis, David R Webb, Kamlesh Khunti, Melanie J Davies
AIMS: To compare efficacy and safety of glucagon-like peptide-1 receptor agonists (GLP-1RAs) in subjects with type 2 diabetes MATERIALS AND METHODS: We electronically searched, up to June 3(rd) , 2016, published randomised clinical trials lasting between 24 and 32 weeks and comparing a GLP-1RA (albiglutide, dulaglutide, twice-daily (EBID) and once-weekly exenatide, liraglutide, lixisenatide, semaglutide, and taspoglutide) with placebo or another GLP-1RA. Data on cardiometabolic and safety outcomes were analysed using a mixed-treatment comparison meta-analysis RESULTS: 34 trials (14464 participants) met the inclusion criteria; no published data for semaglutide were available...
December 15, 2016: Diabetes, Obesity & Metabolism
https://www.readbyqxmd.com/read/27972188/cost-effectiveness-of-exenatide-once-weekly-versus-insulin-glargine-and-liraglutide-for-the-treatment-of-type-2-diabetes-in-greece
#14
C Tzanetakos, A Bargiota, G Kourlaba, N Maniadakis
No abstract text is available yet for this article.
November 2016: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/27972179/healthcare-resource-utilisation-associated-with-patients-treated-with-either-exenatide-once-weekly-or-basal-insulin-a-retrospective-uk-database-analysis
#15
Q Qiao, C L Morgan, S Jenkins-Jones, E Berni, C J Currie, S E Holden
No abstract text is available yet for this article.
November 2016: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/27972164/real-world-tolerability-and-effectiveness-of-exenatide-once-weekly-compared-to-basal-insulin-among-elderly-patients-with-type-2-diabetes-t2d
#16
J D Seeger, A M Loughlin, Q Qiao, A P Nunes, S Ezzy, L A Yochum, C R Clifford, R Gately, P Ohman, D D Dore
No abstract text is available yet for this article.
November 2016: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/27972160/assessment-of-race-specific-tolerability-and-effectiveness-of-exenatide-once-weekly-or-basal-insulin-among-patients-with-type-2-diabetes-in-a-real-world-setting-in-the-usa
#17
J D Seeger, A P Nunes, A M Loughlin, Q Qiao, S Ezzy, L A Yochum, C R Clifford, R Gately, P Ohman, D D Dore
No abstract text is available yet for this article.
November 2016: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/27972158/hemoglobin-a1c-a1c-reduction-and-diabetes-related-health-care-costs-among-type-2-diabetes-t2dm-patients-treated-with-liraglutide-or-exenatide-a-retrospective-claims-database-analysis
#18
M Mocarski, Y Tian, E K Buysman, R Wolbeck
No abstract text is available yet for this article.
November 2016: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/27943107/the-efficacy-of-ideglira-insulin-degludec-liraglutide-combination-in-adults-with-type-2-diabetes-inadequately-controlled-with-a-glp-1-receptor-agonist-and-oral-therapy-dual-iii-randomized-clinical-trial
#19
Sultan Linjawi, Bruce W Bode, Louis B Chaykin, Jean-Pierre Courrèges, Yehuda Handelsman, Lucine M Lehmann, Abhishek Mishra, Richard W Simpson
INTRODUCTION: The progressive nature of type 2 diabetes necessitates treatment intensification. This often involves intensification with oral antidiabetic drugs (OADs) initially, followed by other agents, such as glucagon-like peptide-1 receptor agonists (GLP-1RAs), with the majority of patients eventually requiring insulin therapy. Therefore, this trial aimed to investigate the efficacy of IDegLira (combination of insulin degludec and liraglutide) in controlling glycemia in adults with type 2 diabetes who were inadequately controlled on a GLP-1RA and OADs...
December 10, 2016: Diabetes Therapy: Research, Treatment and Education of Diabetes and related Disorders
https://www.readbyqxmd.com/read/27941058/acute-effects-of-the-glucagon-like-peptide-1-receptor-agonist-exenatide-on-blood-pressure-and-heart-rate-responses-to-intraduodenal-glucose-infusion-in-type-2-diabetes
#20
Sony S Thazhath, Chinmay S Marathe, Tongzhi Wu, Jessica Chang, Joan Khoo, Paul Kuo, Helen L Checklin, Michelle J Bound, Rachael S Rigda, Michael Horowitz, Karen L Jones, Christopher K Rayner
AIM: To evaluate the effects of the glucagon-like peptide-1 receptor agonist, exenatide, on blood pressure and heart rate during an intraduodenal glucose infusion in type 2 diabetes. METHODS: Nine subjects with type 2 diabetes were randomised to receive intravenous exenatide or saline control in a crossover design. Glucose (3 kcal min(-1)) was infused via an intraduodenal manometry catheter for 60 min. Blood pressure, heart rate, and the frequency and amplitude of duodenal pressure waves were measured at regular intervals...
January 2017: Diabetes & Vascular Disease Research
keyword
keyword
11940
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"